Sandoz Files US Trastuzumab With EirGenix
Five Separate Herceptin Biosimilars Are Already Competing In US Market
Sandoz has filed the proposed trastuzumab biosimilar developed by partner EirGenix with the US FDA. If approved, the product will have to compete in an already busy market for Herceptin biosimilars.
You may also be interested in...
Sandoz’ partnership with China’s Gan & Lee covering three biosimilar insulin products continues to make progress, with the conclusion of a pair of Phase III trials involving a proposed biosimilar to Lantus (insulin glargine).
Sandoz has plugged another gap in its off-patent oncology pipeline, from which the company has rolled-out four marketed oncology biosimilars, by bringing in Bio-Thera Solutions’ BAT1706 proposed biosimilar to Avastin, including in the US and Europe.
Taiwan’s EirGenix has made progress with its trastuzumab biosimilar for breast cancer, EG12014, announcing positive Phase III clinical results for the Herceptin equivalent.